Attitude of Libyan Pharmacist In Western Regionof Libya Toward Zantac With drawal
DOI:
https://doi.org/10.54361/ljmr15.1.01Keywords:
withdrawal, pharmacovigilance, ranitidine, attitude, LibyaAbstract
Post-marketing drug withdrawals can be associated with various events, ranging from safety issues such as reported deaths or severe side-effects, to a multitude of non-safety problems including lack of efficacy, manufacturing, regulatory or business issues. During the last century, the majority of drugs voluntarily withdrawn from the market or prohibited by regulatory agencies was reported to be related to adverse drug reactions. Understanding the under lying mechanisms of toxicity is of utmost importance for current and future drug discovery. A questioner review about Libyan pharmacist attitude toward Zantac withdrawal in the western region of Libya. Thedata then was evaluated by Microsoft Excel software for analysis. The total number of responses received was 67, and these responses were from different cities in the west of Libya during 6months study 2020. Highlighting the different sources of knowledge regarding the withdrawal decision, 64.1 % got the information through social media. 32.8 % of the pharmacists after getting the information regarding Ranitidine withdrawal returned it to the company from which bought it. 83.6% of the pharmacist when asked about ranitidine cause of drawing clarified that the ranitidine contains carcinogenic substances. 37.3% of participants mentioned that pharmacovigilance means the detection of problems related to drugs after marketing and use by patients. The aim of this work is to know whether Libya really has drug control and how to deal with medicines that are withdrawn from the market by international organizations andto analyze the know ledgeand attitudeof Libyan pharmacists in western region of Libya about Zantac withdrawn from the market. From the results of a questionnaire conducted in the western regions about knowledge and attitude of Libyan pharmacists toward Zantac withdraw from the market, we concluded that a small percentage of Zantac products have been withdrawn and the doctors are still prescribing and pharmacists are dispensing ranitidine, whether it is OTC or POM.
Downloads
References
Shalini, S., Lynch. Drug Effectiveness and Safety. MSD Manual Consumer Version. Jul 2019
Sullivan JW. A pharmaceutical manufacturer’s perspective on reporting adverse drug experiences. Am J Hosp Pharm. 1990;47:1342–5
Anonymous New contraindication added to Reclast drug label. Reactions Weekly. 2011;1368:3
Thomas SK, Hodson J, McIlroy G, Dhami A, Coleman JJ. The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis. Drug Saf. 2013;36:557–64-013- 0057-3.
Jessica A. Ritsick, Jay W. Cormier & John R. Fleder . Did FDA Shed Light on the Meaning of “Market Withdrawal” in the Updated RPM? Unfortunately, No. Hyman, Phelps & McNamara, P.C. October 31, 2013,https://www.fdalawblog.net/2013/10/did- fda-shed-light-on-the-meaning-of market-withdrawal-in-the-updated-rpm-unfortunately- no-1.
https://www.lawinsider.com/dictionary/market-withdrawal .
Onella Charles,1 IghoOnakpoya, 2 Simran Benipal, ,1 Hannah Woods,1 Anjli Bali,1 Jeffrey K. Aronson, ,2 Carl Heneghan Nav Persaud, . Withdrawn medicines included in the essential medicines lists of 136 countries. PLoS One. 2019 Dec2.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Mabroukah Amr Ishrayhah, Einass ragab ibrahiem (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
